World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Immunology
UK
2026

D-Index & Metrics

Best Scientists

D-Index
189
Citations
176724
World Ranking
437
National Ranking
44

Immunology

D-Index
189
Citations
177513
World Ranking
23
National Ranking
1

Medicine

D-Index
190
Citations
178992
World Ranking
255
National Ranking
29

Research.com Recognitions

  • 2026 - Research.com Immunology in United Kingdom Leader Award
  • 2026 - Research.com Medicine in United Kingdom Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Immunology in United Kingdom Leader Award
  • 2025 - Research.com Medicine in United Kingdom Leader Award
  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

Paul Emery is affiliated with the University of Leeds in the United Kingdom. Their research primarily spans the domain of Medicine, with a focus on Rheumatology and related subfields such as Immunology, Pathology and Forensic Medicine, Hematology, and Genetics.

The scientist's work concentrates on several key topics within medical research, including Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Autoimmune and Inflammatory Disorders Research, Chronic Lymphocytic Leukemia Research, Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment, as well as Systemic Sclerosis and Related Diseases.

Frequent publication venues for Paul Emery include Annals of the Rheumatic Diseases, Lara D. Veeken, RMD Open, The Lancet Rheumatology, and Arthritis Research & Therapy.

The following are some of their recent papers along with publication year and venue:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, 2020, Annals of the Rheumatic Diseases
  • Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia, 2020, The Lancet Rheumatology
  • Rheumatoid arthritis, 2023, The Lancet
  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement, 2020, Annals of the Rheumatic Diseases
  • Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity, 2020, Nature Communications

Paul Emery collaborates frequently with several co-authors. Notable among these are Kulveer Mankia, Andrea Di Matteo, Laurence Duquenne, Edward M Vital, and Leticia Garcia-Montoya.

Best Publications

  • 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

    Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

    P E Lipsky;D M van der Heijde;E W St Clair;D E Furst

  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

    R Maini;E W St Clair;F Breedveld;D Furst

  • Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

    Jonathan C W Edwards;Leszek Szczepanski;Jacek Szechinski;Anna Filipowicz-Sosnowska

  • Treating rheumatoid arthritis to target: recommendations of an international task force

    Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados

  • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

    Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

    Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk

  • Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

    Eli A Stahl;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Gang Xie

  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

    E William St Clair;Désirée M F M van der Heijde;Josef S Smolen;Ravinder N Maini

  • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

    Paul Emery;Roy Fleischmann;Anna Filipowicz-Sosnowska;Joy Schechtman

  • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

    J Braun;R van den Berg;X Baraliakos;H Boehm

  • Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

    R A Luqmani;P A Bacon;R J Moots;B A Janssen

  • Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist

    Barry Bresnihan;José Maria Alvaro‐Gracia;Mark Cobby;Michael Doherty

  • A simplified disease activity index for rheumatoid arthritis for use in clinical practice

    J.S. Smolen;F.C. Breedveld;M.H. Schiff;J.R. Kalden

  • Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

    Gerald B. Appel;Gabriel Contreras;Mary Anne Dooley;Ellen M. Ginzler

  • New therapies for treatment of rheumatoid arthritis

    Josef S Smolen;Daniel Aletaha;Marcus Koeller;Michael H Weisman

  • Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

    R N Maini;P C Taylor;J Szechinski;K Pavelka

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados

Frequent Co-Authors

Dennis McGonagle
Dennis McGonagle University of Leeds
Richard J. Wakefield
Richard J. Wakefield University of Leeds
Philip G. Conaghan
Philip G. Conaghan University of Leeds
Maxime Dougados
Maxime Dougados Hôpital Cochin
Josef S. Smolen
Josef S. Smolen Medical University of Vienna
John D. Isaacs
John D. Isaacs Newcastle University
Ann W. Morgan
Ann W. Morgan University of Leeds
Mikkel Østergaard
Mikkel Østergaard University of Copenhagen
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Robert Landewé
Robert Landewé University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open rewarding career pathways. Nursing professionals often expand into specialized roles such as Family Nurse Practitioner (FNP) or Psychiatric-Mental Health Nurse Practitioner (PMHNP), which complement immunology knowledge with clinical expertise.

If you’re considering further education, exploring the easiest fnp program can help identify online options that balance rigor and flexibility. Similarly, selecting from the top pmhnp programs ensures access to strong clinical placement opportunities, crucial for hands-on experience.

Cost is also a major consideration. The cheapest online pmhnp programs offer budget-friendly pathways without sacrificing program quality, making advanced education more accessible.

Advanced degrees like the Doctor of Nursing Practice (DNP) can lead to competitive salaries. Understanding how much do dnps make by state can guide your career planning and financial expectations post-degree.

Overall, combining immunology with nursing specialties through these online programs can enhance clinical skills and expand career horizons in healthcare.

Best Scientists Citing Paul Emery

Trending Scientists